Guizhou Sanli Pharmaceutical Co Ltd
603439
Company Profile
Business description
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
Contact
Xiayun Industrial Park
Pingba District
Guizhou Province
Anshun561000
CHNT: +86 85138113395
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,852
Stocks News & Analysis
stocks
Have the 3 biggest losers of the ASX 200 fallen too far?
Finding value in some of the ASX’s worst recent performers.
stocks
Rethinking the way we invest in Aussie tech
Investing in Tech companies has many caveats from traditional investing. Let’s dive into how you can gauge the true profitability of a tech company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,866.40 | 56.60 | -0.63% |
| CAC 40 | 8,097.00 | 25.71 | -0.32% |
| DAX 40 | 23,589.44 | 247.35 | -1.04% |
| Dow JONES (US) | 47,560.87 | 155.55 | -0.33% |
| FTSE 100 | 9,702.53 | 17.98 | -0.18% |
| HKSE | 26,033.26 | 174.37 | 0.67% |
| NASDAQ | 23,341.85 | 23.83 | -0.10% |
| Nikkei 225 | 49,303.28 | 950.63 | -1.89% |
| NZX 50 Index | 13,448.49 | 40.66 | -0.30% |
| S&P 500 | 6,841.04 | 8.05 | -0.12% |
| S&P/ASX 200 | 8,565.20 | 48.90 | -0.57% |
| SSE Composite Index | 3,914.01 | 25.41 | 0.65% |